PMID- 25316597
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20221207
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 17
DP  - 2014 Dec
TI  - The potential role of sodium glucose co-transporter 2 inhibitors in combination 
      therapy for type 2 diabetes mellitus.
PG  - 2565-85
LID - 10.1517/14656566.2014.968551 [doi]
AB  - INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class 
      of glucose-lowering agents developed for the treatment of type 2 diabetes 
      mellitus (T2DM). These agents have a mechanism of action that is independent of 
      pancreatic beta-cell function or the degree of insulin resistance; consequently, 
      SGLT2 inhibitors have the potential to be used not only as monotherapy but also 
      in combination with any of the existing classes of glucose-lowering agents, 
      including insulin. As part of the extensive clinical development programs for 
      modern T2DM therapies, SGLT2 inhibitors have been studied in combination with the 
      most commonly used classes of glucose-lowering medications. AREAS COVERED: This 
      report summarizes the key clinical trials data for combination therapies using 
      SGLT2 inhibitors currently approved in the United States and/or the European 
      Union, namely, dapagliflozin, canagliflozin, and empagliflozin. EXPERT OPINION: 
      When given as add-on combination therapy with other glucose-lowering agents, or 
      as monotherapy, SGLT2 inhibitors produced modest but clinically meaningful 
      reductions in glycated hemoglobin, body weight, and systolic blood pressure. 
      These changes have been sustained over long-term follow-up. SGLT2 inhibitors have 
      a generally favorable safety profile similar to that of placebo, and are well 
      tolerated. The risk of hypoglycemia appears to depend on coadministered 
      glucose-lowering agents: when used as monotherapy, the frequency is comparable to 
      that of placebo, but an increased risk is associated with concomitant use of 
      sulfonylureas or insulin. In addition, an increased risk of genitourinary 
      infections has been reported with SGLT2 inhibitors. However, these infections are 
      usually mild, nonrecurrent, and respond to standard treatment.
FAU - Lajara, Rosemarie
AU  - Lajara R
AD  - Diabetes America, Health Center at Plano , Plano, TX , USA 
      rlajara@diabetesamerica.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141015
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Benzhydryl Compounds/adverse effects/therapeutic use
MH  - Canagliflozin
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Drug Therapy, Combination
MH  - Glucose/metabolism
MH  - Glucosides/adverse effects/therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/adverse effects/therapeutic use
OTO - NOTNLM
OT  - canagliflozin
OT  - combination therapy
OT  - dapagliflozin
OT  - empagliflozin
OT  - sodium glucose co-transporter type 2 inhibitors
OT  - type 2 diabetes mellitus
EDAT- 2014/10/16 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/10/16 06:00
PHST- 2014/10/16 06:00 [entrez]
PHST- 2014/10/16 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 10.1517/14656566.2014.968551 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 
      10.1517/14656566.2014.968551. Epub 2014 Oct 15.